Tarsus Q2 XDEMVY sales $173.9M (+69% YoY); raises FY guidance to $685-705M; acquires Alkeus

Tarsus Pharmaceuticals, Inc.

XDEMVY net product sales $173.9M in Q2 2026, up >69% YoY; full-year guidance raised to $685-705M.
Net loss narrowed to $18.6M ($0.43 loss per share) from $20.3M ($0.48) in Q2 2025.
Cash, cash equivalents and marketable securities $449.7M as of June 30, 2026.
Announced agreement to acquire Alkeus Pharmaceuticals (Phase 3 Stargardt disease therapy) and $125M private placement.
Appointed Neera Clase as Interim Chief Commercial Officer; pipeline milestones on track.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.